Id2 regulates the proliferation of squamous cell carcinoma in vitro via the NF-κB/cyclin D1 pathway

Chinese Journal of Cancer

Volumn 31, Issue 9, 2012, Pages 430-439

  Wang, Chuan ^a   Chen, Qiang ^a   Hamajima, Yuki ^b   Sun, Wei ^c   Zheng, Yi Qing ^c   Hu, Xiao Hua ^a   Ondrey, Frank G ^d   Lin, Ji Zhen ^a,d  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cyclin D1; Head and neck squamous cell carcinoma; Human; Id2; NF B

Indexed keywords

CYCLIN D1; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF DIFFERENTIATION 2; MESSENGER RNA; PYRROLIDINE DITHIOCARBAMATE; SYNAPTOTAGMIN I;

ARTICLE; BINDING SITE; CANCER GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE FUNCTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INHIBITOR OF DIFFERENTIATION 2 GENE; MOLECULAR PATHOLOGY; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATOR GENE; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; TRANSIENT TRANSFECTION; UPREGULATION;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; HEAD AND NECK NEOPLASMS; HUMANS; I-KAPPA B PROTEINS; INHIBITOR OF DIFFERENTIATION PROTEIN 2; NF-KAPPA B; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84866597524     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10454     Document Type: Article

References (57)

1. Norton JD, Deed RW, Craggs G, et al. Id helix-loop-helix proteins in cell growth and differentiation. Trends Cell Biol, 1998,8:58-65.
2. Alani RM, Hasskarl J, Grace M, et al. Immortalization of primary human keratinocytes by the helix-loop-helix protein, Id-1. Proc Natl Acad Sci USA, 1999,96:9637-9641.
3. Jogi A, Persson P, Grynfeld A, et al. Modulation of basic helix-loop-helix transcription complex formation by Id proteins during neuronal differentiation. J Biol Chem, 2002,277:9118-9126.
4. Massari ME, Murre C. Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol, 2000,20: 429-440.
5. Grandori C, Cowley SM, James LP, et al. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol, 2000,16:653-699.
6. Baudino TA, Cleveland JL. The Max network gone mad. Mol Cell Biol, 2001,21:691-702.
7. Martinsen BJ, Bronner-Fraser M. Neural crest specification regulated by the helix-loop-helix repressor Id2. Science, 1998,281:988-991.
8. Becker-Herman S, Lantner F, Shachar I. Id2 negatively regulates B cell differentiation in the spleen. J Immunol, 2002,168:5507-5513.
9. Norton JD. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci, 2000,113:3897-3905.
10. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996,86:353-364.
11. Andres-Barquin PJ, Hernandez MC, Hayes TE, et al. Id genes encoding inhibitors of transcription are expressed during in vitro astrocyte differentiation and in cell lines derived from astrocytic tumors. Cancer Res, 1997,57:215-220.
12. Deed RW, Bianchi SM, Atherton GT, et al. An immediate early human gene encodes an Id-like helix-loop-helix protein and is regulated by protein kinase C activation in diverse cell types. Oncogene, 1993,8:599-607.
13. Zhu W, Dahmen J, Bulfone A, et al. Id gene expression during development and molecular cloning of the human ld-1 gene. Brain Res Mol Brain Res, 1995,30:312-326.
14. lavarone A, Garg P, Lasorella A, et al. The helix-loop-helix protein ld-2 enhances cell proliferation and binds to the retinoblastoma protein. Genes Dev, 1994,8:1270-1284.
15. Lasorella A, lavarone A, Israel MA. Id2 specifically alters regulation of the cell cycle by tumor suppressor proteins. Mol Cell Biol, 1996,16:2570-2578.
16. Vandeputte DA, Troost D, Leenstra S, et al. Expression and distribution of id helix-loop-helix proteins in human astrocytic tumors. Glia, 2002,38:329-338.
17. Lasorella A, Boldrini R, Dominici C, et al. Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res, 2002,62:301-306.
18. Nishimori H, Sasaki Y, Yoshida K, et al. The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors. Oncogene, 2002,21:8302-8309.
19. Wilson JW, Deed RW, Inoue T, et al. Expression of Id helix-loop-helix proteins in colorectal adenocarcinoma correlates with p53 expression and mitotic index. Cancer Res, 2001,61:8803-8810.
20. Rockman SP, Currie SA, Ciavarella M, et al. Id2 is a target of the beta-catenin/T cell factor pathway in colon carcinoma. J Biol Chem, 2001,276:45113-45119.
21. Wice BM, Gordon JI. Forced expression of ld-1 in the adult mouse small intestinal epithelium is associated with development of adenomas. J Biol Chem, 1998,273:25310-25319.
22. Lin J, Guan Z, Wang C, et al. Id1 regulates the survival of HNSCC via the NF-kappaB/survivin and PI3K/Akt signaling pathways. Clin Cancer Res, 2010,16:77-87.
23. Lasorella A, Noseda M, Beyna M, et al. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature, 2000,407:592-598.
24. Lyden D, Young AZ, Zagzag D, et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature, 1999,401:670-677.
25. Langlands K, Down GA, Kealey T. Id proteins are dynamically expressed in normal epidermis and dysregulated in squamous cell carcinoma. Cancer Res, 2000,60:5929-5933.
26. Kato T, Duffey DC, Ondrey FG, et al. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and trancription factor NF-kappa B. Head Neck, 2000,22:748-759.
27. Rhim JS, Jay G, Arnstein P, et al. Neoplastic transformation of human epidermal keratinocytes by AD12-SV40 and Kirsten sarcoma viruses. Science, 1985,227:1250-1252.
28. Franzoso G, Bours V, Azarenko V, et al. The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites. EMBO J, 1993,12:3893-3901.
29. Israel DI, Kaufman RJ. Highly inducible expression from vectors containing multiple GRE's in CHO cells overexpressing the glucocorticoid receptor. Nucleic Acids Res, 1989,17:4589-4604.
30. Bours V, Franzoso G, Azarenko V, et al. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell, 1993,72: 29-739.
31. Bressier P, Brown K, Timmer W, et al. Mutational analysis of the p50 subunit of NF-kappa B and inhibition of NF-kappa B activity by trans-dominant p50 mutants. J Virol, 1993,67:288-293.
32. Brockman JA, Scherer DC, McKinsey TA, et al. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol, 1995,15: 2809-2818.
33. Ziegler-Heitbrock HW, Sternsdorf T, Liese J, et al. Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes. J Immunol, 1993,151:6986-6993.
34. Albanese C, Johnson J, Watanabe G, et al. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem, 1995,270:23589-23597.
35. Kanno T, Brown K, Siebenlist U. Evidence in support of a role for human T-cell leukemia virus type I Tax in activating NF-kappa B via stimulation of signaling pathways. J Biol Chem, 1995,270:11745-11748.
36. Lin J, Tsuprun V, Kawano H, et al. Characterization of mucins in human middle ear and Eustachian tube. Am J Physiol, 2001,280:L1157-L1167.
37. Ginos MA, Page GP, Michalowicz BS, et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res, 2004,64:55-63.
38. Guttridge DC, Albanese C, Reuther JY, et al. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol, 1999,19:5785-5799.
39. Joyce D, Bouzahzah B, Fu M, et al. Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway. J Biol Chem, 1999,274:25245-25249.
40. Henry DO, Moskalenko SA, Kaur KJ, et al. Ral GTPases contribute to regulation of cyclin D1 through activation of NF-kappaB. Mol Cell Biol, 2000,20:8084-8092.
41. Westerheide SD, Mayo MW, Anest V, et al. The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition. Mol Cell Biol, 2001,21:8428-8436.
42. Sharma HW, Narayanan R. The NF-kappaB transcription factor in oncogenesis. Anticancer Res, 1996,16:589-596.
43. Duffey DC, Chen Z, Dong G, et al. Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res, 1999,59:3468-3474.
44. Darnell JEJ. Transcription factors as targets for cancer therapy. Nat Rev Cancer, 2002,2:740-749.
45. Orlowski RZ, Baldwin ASJ. NF-kappaB as a therapeutic target in cancer. Trends Mol Med, 2002,8:385-389.
46. Biswas DK, Cruz AP, Gansberger E, et al. Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA, 2000,97:8542-8547.
47. Haridas V, Darnay BG, Natarajan K, et al. Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis,nuclear factor-kappa B activation, and c-Jun kinase activation. J Immunol, 1998,160:3152-3162.
48. Henkel T, Machleidt T, Alkalay I, et al. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature, 1993,365:182-185.
49. Brown K, Gerstberger S, Carlson L, et al. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science, 1995,267:1485-1488.
50. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell, 2000,100:57-70.
51. Pestell RG, Albanese C, Reutens AT, et al. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev, 1999,20:501-534.
52. Jares P, Fernandez PL, Campo E, et al. PRAD-1/cyclin D1 gene amplification correlates with messenger RNA over-expression and tumor progression in human laryngeal carcinomas. Cancer Res, 1994,54:4813-4817.
53. Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck, 2001,23:147-159.
54. Namazie A, Aiavi S, Olopade OI, et al. Cyciin D1 amplification and p16(MTS1/CDK4l) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope, 2002,112:472-481.
55. Weinberg RA. The retinobiastoma protein and cell cycle control. Cell, 1995,81:323-330.
56. Sherr CJ. Mammalian G1 cyclins. Cell, 1993,73:1059-1065.
57. Tashiro E, Maruki H, Minato Y, et al. Overexpression of cyciin D1 contributes to malignancy by up-regulation of fibroblast growth factor receptor 1 via the pRB/E2F pathway. Cancer Res, 2003,63:424-431.